1. 何强,郭玉宁,徐有青*.代谢综合征及相关组分对复发性急性胰腺炎预后的评估价值.中国临床医生杂志.2023.51(02).180-183.核心期刊 |
2. Yanfei Lang, Xiaxia Zhang, Xin Li, Youqing Xu*.The mitophagosome, a novel ultrastructure of mitophagy in the alcoholic steatohepatitis mouse model: a transmission electron microscope study.Ultrastructural Pathology.2022.46(3).251-258.SCI |
3. 王天懿,邵翠萍,徐有青*..隐源性肝硬化42例临床诊断分析.中国医刊.2022.57(01).88-91.核心期刊 |
4. 张莹,李静,徐有青*.血清CEA、AFP、CA199、CA125联合检测诊断胃癌的ROC曲线分析及临床指导意义.湖南师范大学学报(医学版).2022.19(04).81-84.核心期刊 |
5. Zhang X X, Lang Y F, Li X, Li, Z,Xu, YQ*,Chu, H Q.The protective effect of puerarin-loaded mesoporous silicon nanoparticles on alcoholic hepatitis through mTOR-mediated autophagy pathway.Biomedical Microdevices.2022.24(4). .SCI |
6. 何强,于新颖,吕栋,徐有青*..无害性急性胰腺炎评分及体重指数对早期急性高脂血症性胰腺炎严重程度的评估价值.中国临床医生杂志.2022.50(11).1294-1296.核心期刊 |
7. Shao C, Cheng Q, Zhang S, Xiang, X,Xu, Y*.Serum level of free thyroxine is an independent risk factor for non-alcoholic fatty liver disease in euthyroid people.Annals of Palliative Medicine.2022.11(2).655-662.SCI |
8. 王天懿,李鑫,徐有青*.酒精性肝硬化与非酒精性脂肪性肝硬化的临床特征比较.中国医刊.2022.57(08).848-850.核心期刊 |
9. Liu L.,Guo H.,Shao C.,Wang, L,Xu, Y*,Zhou, Y.Shugan Huoxue Huayu Fang (疏肝活血化瘀方) attenuates carbon tetrachloride-induced hepatic fibrosis in rats by inhibiting transforming growth factor-β1/Smad signaling.Journal of Traditional Chinese Medicine.2022.42(1).65-72.SCI |
10. 李静,徐有青*.内镜黏膜下剥离术与内镜下黏膜切除术治疗早期胃癌的效果及术后出血的影响因素分析.中国肿瘤外科杂志.2021.13(04).380-383.核心期刊 |
11. 于新颖,吕栋,李昂,徐有青*.消化道病变内镜黏膜下剥离术临床效果及学习曲线分析.中华肿瘤防治杂志.2021.28(19).1503-1508.核心期刊 |
12. Zhang Y, Li J, Xu Y*.Association of Incidence between Pancreatic Adipose Infiltration and Metabolic Syndrome: A Literature Review and Meta-analysis.Computational and Mathematical Methods in Medicine.2021. . .SCI |
13. Zhang H, Jia L, Xu Y*.Etiologies of remarkably elevated serum levels of carbohydrate antigen 19-9[J]. Journal of B.U.ON..Journal of B.U.ON..2021.26(4).1653-1658.SCI |
14. Yu, X Y,Lyu, D,Li, A,Xu, YQ*.Clinical effect and learning curve analysis of endoscopic submucosal dissection of digestive tract lesions.Chinese Journal of Cancer Prevention and Treatment.2021.28(19).1503-1508. |
15. Shao C, Xu Y*.Association of serum uric acid - To - creatinine ratio with nonalcoholic fatty liver disease.Journal of Clinical Hepatology.2021.37(7).2348-2351. |
16. Li J, Li X, Zhang H, Xu, Y*.Value of contrast - enhanced endoscopic ultrasound versus contrast - enhanced computed tomography in the diagnosis of pancreatic solid space - occupying lesions.Journal of Clinical Hepatology.2021.37(7).1648-1651. |
17. 邵翠萍,徐有青*..血清尿酸/肌酐比值与非酒精性脂肪性肝病的相关性分析[J]. 临床肝胆病杂志.临床肝胆病杂志.2021.37(10).2348-2351.核心期刊 |
18. 李静,李鑫,张辉,徐有青* .癌胚抗原、糖类抗原125、糖类抗原199对Ⅲ期结肠癌根治术后患者预后的价值.中国临床医生杂志.2021.49(08).948-951.核心期刊 |
19. 贾雷,于新颖,徐丽娟,徐有青*.基于生物信息学刻画ⅡB期胰腺癌的免疫微环境特征和预后的差异.消化肿瘤杂志.2021.13(02).114-119.核心期刊 |
20. 邵翠萍,徐有青*.甲状腺激素与非酒精性脂肪性肝病的相关性分析.中国医药.2021.16(08).1209-1212.核心期刊 |
21. 李鑫,胡梦琪,郎艳飞,徐有青*.超声内镜对脂肪胰的诊断及相关临床因素分析.中南医学科学杂志.2020.48(01).72-75.核心期刊 |
22. 邵翠萍,徐有青*.血清CA724水平与胃恶性肿瘤相关性的Meta分析.中国医药生物技术.2020.15(02).178-182.核心期刊 |
23. 王天懿,王麟,徐有青*.非酒精性脂肪性肝硬化的临床特征及回顾性分析.中国临床医生杂志.2020.48(09).1055-1058.核心期刊 |
24. Fan X, Jin J, Yan L, Liu, L,Li, Q,Xu, Y*.The impaired anti-tumoral effect of immune surveillance cells in the immune microenvironment of gastric cancer.Clinical Immunology.2020.219. .SCI |
25. 何强,吕栋,崔培林,徐有青*.复发性高脂血症性急性胰腺炎临床特点分析.临床和实验医学杂志.2019.18(06).617-619.核心期刊 |
26. 张莹,王洪岩,迟程,徐有青*.LPS诱导的HepG2细胞NOTCH与LPS-TLR4-NF-κB炎症信号通路的“会话”研究.实用肝脏病杂志.2019.22(04).470-473.核心期刊 |
27. 邵翠萍,徐有青* .肝硬化患者血清CA125水平与肝损害程度相关性的Meta分析.临床肝胆病杂志.2019.35(04).796-800.核心期刊 |
28. 何强,张辉,吕栋,崔培林,徐有青*.代谢综合征相关组分与结直肠绒毛状腺瘤相关性研究.临床和实验医学杂志.2019.18(05).519-521.核心期刊 |
29. 贾雷,郭玉宁,郭秀丽,王天懿,吕栋,徐有青.超声内镜与磁共振胰胆管造影诊断梗阻性黄疸的效果比较.临床肝胆病杂志.2016.32(9).1753-1755.核心期刊 |
30. 何强,徐有青*.超声内镜诊断消化道肿瘤的临床价值.中国实用内科杂志.2015.35(5).202-204.核心期刊 |
31. 李静,李鑫,张辉,徐有青*.造影增强超声内镜与增强CT对胰腺实性占位诊断价值的比较分析.临床肝胆病杂志. .37(07).1648-1651.核心期刊 |